This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arvin, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arvin, A. M.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, Jul 1996, 361-381, Vol 9, No. 3
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Varicella-zoster virus

AM Arvin
Department of Pediatrics, Stanford University School of Medicine, California 94305-5119, USA. MN.AMA@FORSYTHE.STANFORD.EDU

Varicella-zoster virus (VZV) is a ubiquitous human alphaherpesvirus that causes varicella (chicken pox) and herpes zoster (shingles). Varicella is a common childhood illness, characterized by fever, viremia, and scattered vesicular lesions of the skin. As is characteristic of the alphaherpesviruses, VZV establishes latency in cells of the dorsal root ganglia. Herpes zoster, caused by VZV reactivation, is a localized, painful, vesicular rash involving one or adjacent dermatomes. The incidence of herpes zoster increases with age or immunosuppression. The VZV virion consists of a nucleocapsid surrounding a core that contains the linear, double-stranded DNA genome; a protein tegument separates the capsid from the lipid envelope, which incorporates the major viral glycoproteins. VZV is found in a worldwide geographic distribution but is more prevalent in temperate climates. Primary VZV infection elicits immunoglobulin G (IgG), IgM, and IgA antibodies, which bind to many classes of viral proteins. Virus-specific cellular immunity is critical for controlling viral replication in healthy and immunocompromised patients with primary or recurrent VZV infections. Rapid laboratory confirmation of the diagnosis of varicella or herpes zoster, which can be accomplished by detecting viral proteins or DNA, is important to determine the need for antiviral therapy. Acyclovir is licensed for treatment of varicella and herpes zoster, and acyclovir, valacyclovir, and famciclovir are approved for herpes zoster. Passive antibody prophylaxis with varicella- zoster immune globulin is indicated for susceptible high-risk patients exposed to varicella. A live attenuated varicella vaccine (Oka/Merck strain) is now recommended for routine childhood immunization.


This article has been cited by other articles:

  • Walters, M. S., Erazo, A., Kinchington, P. R., Silverstein, S. (2009). Histone Deacetylases 1 and 2 Are Phosphorylated at Novel Sites during Varicella-Zoster Virus Infection. J. Virol. 83: 11502-11513 [Abstract] [Full Text]  
  • Moltedo, B., Lopez, C. B., Pazos, M., Becker, M. I., Hermesh, T., Moran, T. M. (2009). Cutting Edge: Stealth Influenza Virus Replication Precedes the Initiation of Adaptive Immunity. J. Immunol. 183: 3569-3573 [Abstract] [Full Text]  
  • Perella, D., Fiks, A. G., Jumaan, A., Robinson, D., Gargiullo, P., Pletcher, J., Forke, C. M., Schmid, D. S., Renwick, M., Mankodi, F., Watson, B., Spain, C. V. (2009). Validity of Reported Varicella History as a Marker for Varicella Zoster Virus Immunity Among Unvaccinated Children, Adolescents, and Young Adults in the Post-Vaccine Licensure Era. Pediatrics 123: e820-e828 [Abstract] [Full Text]  
  • Holmes, M. V., Atabani, S. F, Khan, N., Steiner, K., Haque, T., Slapak, G. (2009). A case for varicella vaccination in the immunosuppressed. BMJ Case Reports 2009: bcr0720080461-bcr0720080461 [Abstract] [Full Text]  
  • Strangfeld, A., Listing, J., Herzer, P., Liebhaber, A., Rockwitz, K., Richter, C., Zink, A. (2009). Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti-TNF-{alpha} Agents. JAMA 301: 737-744 [Abstract] [Full Text]  
  • Khalil, M. I., Hay, J., Ruyechan, W. T. (2008). Cellular Transcription Factors Sp1 and Sp3 Suppress Varicella-Zoster Virus Origin-Dependent DNA Replication. J. Virol. 82: 11723-11733 [Abstract] [Full Text]  
  • Kalthoff, D., Granzow, H., Trapp, S., Beer, M. (2008). The UL49 gene product of BoHV-1: a major factor in efficient cell-to-cell spread. J. Gen. Virol. 89: 2269-2274 [Abstract] [Full Text]  
  • Sjoholm, M. I. L., Dillner, J., Carlson, J. (2008). Multiplex Detection of Human Herpesviruses from Archival Specimens by Using Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. J. Clin. Microbiol. 46: 540-545 [Abstract] [Full Text]  
  • El Mjiyad, N., Bontems, S., Gloire, G., Horion, J., Vandevenne, P., Dejardin, E., Piette, J., Sadzot-Delvaux, C. (2007). Varicella-Zoster Virus Modulates NF-{kappa}B Recruitment on Selected Cellular Promoters. J. Virol. 81: 13092-13104 [Abstract] [Full Text]  
  • Koskiniemi, M., Lappalainen, M., Schmid, D. S., Rubtcova, E., Loparev, V. N. (2007). Genotypic Analysis of Varicella-Zoster Virus and Its Seroprevalence in Finland. CVI 14: 1057-1061 [Abstract] [Full Text]  
  • Kyratsous, C. A., Silverstein, S. J. (2007). BAG3, a Host Cochaperone, Facilitates Varicella-Zoster Virus Replication. J. Virol. 81: 7491-7503 [Abstract] [Full Text]  
  • Burke, M. S. (2007). Herpes Zoster Vaccine: Clinical Trial Evidence and Implications for Medical Practice. JAOA: Journal of the American Osteopathic Association 107: S14-S18 [Abstract] [Full Text]  
  • Loparev, V., Martro, E., Rubtcova, E., Rodrigo, C., Piette, J.-C., Caumes, E., Vernant, J.-P., Schmid, D. S., Fillet, A.-M. (2007). Toward Universal Varicella-Zoster Virus (VZV) Genotyping: Diversity of VZV Strains from France and Spain. J. Clin. Microbiol. 45: 559-563 [Abstract] [Full Text]  
  • Stallings, C. L., Silverstein, S. J. (2006). Posttranslational Modification and Cell Type-Specific Degradation of Varicella-Zoster Virus ORF29p. J. Virol. 80: 10836-10846 [Abstract] [Full Text]  
  • Goldman, G. S. (2006). The Case against Universal Varicella Vaccination. International Journal of Toxicology 25: 313-317 [Abstract] [Full Text]  
  • Stallings, C. L., Duigou, G. J., Gershon, A. A., Gershon, M. D., Silverstein, S. J. (2006). The Cellular Localization Pattern of Varicella-Zoster Virus ORF29p Is Influenced by Proteasome-Mediated Degradation. J. Virol. 80: 1497-1512 [Abstract] [Full Text]  
  • Fletcher, J. M., Vukmanovic-Stejic, M., Dunne, P. J., Birch, K. E., Cook, J. E., Jackson, S. E., Salmon, M., Rustin, M. H., Akbar, A. N. (2005). Cytomegalovirus-Specific CD4+ T Cells in Healthy Carriers Are Continuously Driven to Replicative Exhaustion. J. Immunol. 175: 8218-8225 [Abstract] [Full Text]  
  • Stallings, C. L., Silverstein, S. (2005). Dissection of a Novel Nuclear Localization Signal in Open Reading Frame 29 of Varicella-Zoster Virus. J. Virol. 79: 13070-13081 [Abstract] [Full Text]  
  • Goldman, G. S. (2005). Universal Varicella Vaccination: Efficacy Trends and Effect on Herpes Zoster. International Journal of Toxicology 24: 205-213 [Abstract] [Full Text]  
  • Visalli, R. J., Fairhurst, J., Srinivas, S., Hu, W., Feld, B., DiGrandi, M., Curran, K., Ross, A., Bloom, J. D., van Zeijl, M., Jones, T. R., O'Connell, J., Cohen, J. I. (2003). Identification of Small Molecule Compounds That Selectively Inhibit Varicella-Zoster Virus Replication. J. Virol. 77: 2349-2358 [Abstract] [Full Text]  
  • Kinchington, P. R., Fite, K., Seman, A., Turse, S. E. (2001). Virion Association of IE62, the Varicella-Zoster Virus (VZV) Major Transcriptional Regulatory Protein, Requires Expression of the VZV Open Reading Frame 66 Protein Kinase. J. Virol. 75: 9106-9113 [Abstract] [Full Text]  
  • ENSHELL-SEIJFFERS, D., SMELYANSKI, L., VARDINON, N., YUST, I., GERSHONI, J. M. (2001). Dissection of the humoral immune response toward an immunodominant epitope of HIV: a model for the analysis of antibody diversity in HIV+ individuals. FASEB J. 15: 2112-2120 [Abstract] [Full Text]  
  • Keller, M. A., Stiehm, E. R. (2000). Passive Immunity in Prevention and Treatment of Infectious Diseases. Clin. Microbiol. Rev. 13: 602-614 [Abstract] [Full Text]  
  • Sahli, R., Andrei, G., Estrade, C., Snoeck, R., Meylan, P. R. A. (2000). A Rapid Phenotypic Assay for Detection of Acyclovir-Resistant Varicella-Zoster Virus with Mutations in the Thymidine Kinase Open Reading Frame. Antimicrob. Agents Chemother. 44: 873-878 [Abstract] [Full Text]  
  • Wallace, M. R., Chamberlin, C. J., Zerboni, L., Sawyer, M. H., Oldfield, E. C., Olson, P. E., Arvin, A. M. (1997). Reliability of a History of Previous Varicella Infection in Adults. JAMA 278: 1520-1522 [Abstract]  
  • Barnes, A. J, Johnson, A. S, Shelly, M. P, Orton, C. I (1996). ... but it can occur at any age. BMJ 313: 1145a-1145 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»